Fast-growing Duoning Biotech seeks winning formula for pricey IPO
The provider of bioprocessing services for the drugs sector has been expanding rapidly via aggressive M&A, backed by big-name investors Key Takeaways: WuXi Biologics is Duoning Biotechnology’s biggest client and…
RELATED ARTICLES
-
WuXi Biologics sells vaccine plant as new U.S. law looms
2269.HK -
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK
-
A Drug Company’s Forced Sales, and a Family Feud in Shanghai
2269.HK 2359.HK
-
Zhengye Biotech’s ‘pet-sized’ IPO leaves plenty of room for more fundraising
ZYBT.US
